Results 281 to 290 of about 3,684,448 (359)

Psilocybin Production With Genetically Modified Aspergillus nidulans Under Pressurized Conditions

Biotechnology and Bioengineering, EarlyView.
Shake flask cultures of psilocybin‐producing A. nidulans were investigated with respect to nitrogen source, rheology, power input, and oxygen availability, and subsequently scaled to a stirred tank reactor scale based on specific power input to develop and optimize a pressurized bioprocess.
Sophie Weiser, Sidney Jung, Bettina Bardl, Johann E. Kufs, Slavica Janevska, Vito Valiante, Dirk Hoffmeister, Lars Regestein   +7 more
wiley   +1 more source

Coffee intake is associated with telomere length in severe mental disorders. [PDF]

BMJ Ment Health
Mlakar V, Di Forti M, Halff EF, Srivastava DP, Akkouh I, Djurovic S, Martin-Ruiz C, Quintana DS, Birkenæs V, Steen NE, Ormerod MB, Andreassen OA, Aas M.   +12 more
europepmc   +1 more source

Nanomaterial‐based immune therapeutic strategies in neurodegenerative diseases

BMEMat, EarlyView.
This review highlights the immunomodulatory potential of nanomaterials (NMs) in treating neurodegenerative diseases (NDs). It focuses on their roles in regulating innate and adaptive immune responses to maintain immune homeostasis. By providing insights into these mechanisms, the review lays the groundwork for innovative NMs therapeutic strategies to ...
Xinru Zhou, Jia Liu, Shulin Lai, Suhan Yin, Bingmin Luo, Longquan Shao, Yiyuan Kang   +6 more
wiley   +1 more source

Developing Topics. [PDF]

Alzheimers Dement
Andrews SJ, Mitchell BA, Tong T, Bonham LW, Renton AE, Zhang X, Sirota M, Tosun D, Yaffe K.   +8 more
europepmc   +1 more source

A Natural Resource‐Based View of Circular Economy Practices in the Pharmaceutical Industry

Business Strategy and the Environment, EarlyView.
ABSTRACT Pharmaceutical industry is facing escalating environmental sustainability issues including gaseous emissions, waste generation, and excessive consumption of energy and non‐renewable materials. Nevertheless, the adoption of sustainable business models such as the circular economy (CE) is still in its infancy in this sector due to complex ...
Amna Farrukh, Muhammad Sohaib Sajjad
wiley   +1 more source

The 'Mental Health Crisis' and the Nonbeing of the Mad. [PDF]

Nurs Philos
Domingue JL, Foth T.
europepmc   +1 more source

An Investigation of Hyperostosis Frontalis Interna in a Modern Anatomical Body Donor Population

Clinical Anatomy, EarlyView.
ABSTRACT This research sought to examine the prevalence and severity of hyperostosis frontalis interna (HFI) in the Chicagoland anatomical body donor population. The study further aimed to elucidate potential demographic risk factors for HFI, including sex, age at death, and structural vulnerability index (SVI), as well as any common comorbidities, as ...
Amy C. Beresheim, Amanda Hall
wiley   +1 more source

Lesions Associated With Autism Symptoms Map to a Cerebellar Brain Network in Tuberous Sclerosis Complex

Annals of the Child Neurology Society, EarlyView.
ABSTRACT Objective Autism spectrum disorder (ASD) affects 1 in 36 individuals in the United States and is characterized by impaired social communication and restrictive/repetitive behaviors. Individuals with tuberous sclerosis complex (TSC) have a high incidence of ASD (40%) and exhibit congenital brain lesions (tubers), offering a unique lesion‐based ...
Wendy Xiao Herman, Gillian N. Miller, Mustafa Sahin, Jurriaan M. Peters, Simon K. Warfield, Darcy A. Krueger, E. Martina Bebin, Hope Northrup, Joyce Y. Wu, Michael D. Fox, Alexander L. Cohen   +10 more
wiley   +1 more source

Harnessing Analysis of Individual Differences in Behavior to Identify Novel Mechanisms Relevant to Neuropsychiatric Disorders. [PDF]

Biol Psychiatry Glob Open Sci
Torregrossa MM.
europepmc   +1 more source

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Bexicaserin in Healthy Participants: A First‐in‐Human Randomized, Double‐Blind, Placebo‐Controlled Single Ascending Dose Escalation Phase 1 Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Bexicaserin (LP352) is a selective 5‐hydroxytryptamine 2C (5‐HT2C) superagonist in development for the treatment of seizures in developmental and epileptic encephalopathies (DEEs). This double‐blind, placebo‐controlled, single ascending dose (SAD) Phase 1 study aimed to assess the safety, tolerability, and pharmacokinetic (PK) and ...
Rosa Chan, Chad Orevillo, Gale O'Connell, Dewey McLin, Shikha Polega, Nuggehally R Srinivas, Randall Kaye   +6 more
wiley   +1 more source